Fate Therapeutics (FATE) Analyst & Key Data

Analyst Consensus

Buy4 analysts

Buy

Updated Sep 12, 2026

Total Analysts4

Buy

16

Hold

13

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score1.0 / 5

Debt / Equity Score2.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$2.31

Median Target+143.72%

$5.63

Potential upside vs current price

DCF Value-118.85%

-$0.44

Potential downside vs current price

Current Stock Price

$2.31

Median Target+143.72%

$5.63

Potential upside vs current price

DCF Value-118.85%

-$0.44

Potential downside vs current price

Analyst Consensus

Buy4 analysts

Buy

Updated Sep 12, 2026

Total Analysts4

Buy

16

Hold

13

Sell

2

Ratings

Updated Sep 12, 2026

Overall Rating

C-

DCF Score1.0 / 5

Debt / Equity Score2.0 / 5

Price / Book Score3.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$2.31

Median Target+143.72%

$5.63

Potential upside vs current price

DCF Value-118.85%

-$0.44

Potential downside vs current price

Current Stock Price

$2.31

Median Target+143.72%

$5.63

Potential upside vs current price

DCF Value-118.85%

-$0.44

Potential downside vs current price

Fate Therapeutics, Inc.